MiMedx Group. has been granted a patent for a composition that combines water, soluble collagen, and micronized placental tissue components. This integrated admixture is designed for applications in wound healing, tendon repair, and cosmetic uses, forming a coherent and flexible mass under force. GlobalData’s report on MiMedx Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MiMedx Group, Cardiothoracic surgery instruments was a key innovation area identified from patents. MiMedx Group's grant share as of July 2024 was 59%. Grant share is based on the ratio of number of grants to total number of patents.
Collagen and placental tissue compositions for wound healing
The granted patent US12070528B2 describes a novel composition that integrates water, soluble collagen, and micronized placental tissue components, resulting in an aqueous or gelatinous mixture characterized by apparent homogeneity. This composition can form a coherent and flexible mass when subjected to force or shear. The micronized placental tissue components may include micronized amnion, chorion, and Wharton's jelly, with a particle size of less than 400 µm. The composition can contain human collagen in an aqueous form, typically ranging from 0.1% to 2% by weight, and the weight ratio of micronized placental tissue to collagen can vary from 3:1 to 300:1.
Additionally, the patent outlines methods for transforming the collagen mass into a coherent composition by incorporating micronized placental tissue and applying sufficient force and shear. The methods also specify the use of human collagen and detail the composition's application in treating wounds and cosmetic defects. The claims emphasize the structural integrity of the micronized tissue grafts, which may include layers of amnion and chorion, with specific cellular components preserved. Overall, the patent presents a comprehensive approach to creating a versatile composition with potential therapeutic applications.
To know more about GlobalData’s detailed insights on MiMedx Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
